UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington,D.C.20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934

June 12, 2019

DateofReport(Dateofearliesteventreported)

HELIUS MEDICAL TECHNOLOGIES, INC.
(Exact name of registrant as specified in its charter)

DELAWARE	001-38445	36-4787690
(State or other jurisdiction of	(Commission	(I.R.S. Employer
incorporation or organization)	File Number)	Identification No.)

(Exact nameofregistrant asspecified in charter)

642 Newtown Yardley Road, Suite 100

Newtown, Pennsylvania, 18940

(Address of principal executive offices) (Zip Code)

Registrant’s telephone number, including area code: (215) 944-6100

Check theappropriatebox below iftheForm8-K filing isintended to simultaneously satisfy thefiling obligation oftheregistrantunderany ofthefollowing provisions:

☐ Written communicationspursuanttoRule425undertheSecuritiesAct (17CFR230.425)

☐ Solicitingmaterial pursuanttoRule14a­12undertheExchangeAct (17CFR240.14a­12)

☐ Pre­commencementcommunicationspursuanttoRule14d­2(b)undertheExchangeAct (17CFR240.14d­2(b))

☐ Pre­commencementcommunicationspursuanttoRule13e­4(c)undertheExchangeAct (17CFR240.13e­4(c))

Securities registered pursuant to Section 12(b) of the Exchange Act: 

Title of each class	Trading symbol	Name of each exchange on which registered
Class A Common Stock	HSDT	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b‑2 of the Securities Exchange Act of 1934 (§240.12b‑2 of this chapter).

Emerging growth company ☑

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act ☑

Item 5.07 Submission of Matters to a Vote of Security Holders.

On June 12, 2019, Helius Medical Technologies, Inc. (the “Company”) held its 2019 annual meeting of stockholders (the “Annual Meeting”). The stockholders considered two proposals, each of which is described in more detail in the Company’s definitive proxy statement filed with the Securities and Exchange Commission on April 26, 2019.  Of the 25,866,211 shares of Class A Common Stock outstanding as of the record date, 15,476,277 shares, or 59.83%, were present or represented by proxy at the Annual Meeting.  Set forth below are the results of the matters submitted for a vote of stockholders at the Annual Meeting.

Proposal No. 1:  Election of seven directors of the Company to serve until the 2020 annual meeting of stockholders of the Company and until their respective successors are elected and qualified. The votes were cast as follows:

Name	Votes For		Votes Withheld
Philippe Deschamps	11,143,698		63,752
Dane C. Andreeff	10,930,030		277,420
Thomas E. Griffin		11,175,633	31,817
Huaizheng Peng	11,073,143		134,307
Edward M. Straw		11,149,306	58,144
Mitchell E. Tyler	11,176,198		31,252
Blane Walter		10,609,048	603,402

Broker Non-Votes: 4,268,827

All nominees were elected.

Proposal No. 2:  Ratification of the selection of BDO USA, LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2019. The votes were cast as follows:

	Votes For	Votes Against	Abstained
Ratification of Selection of BDO USA, LLP	15,429,313	14	46,950

The selection of BDO USA, LLP was ratified.

SIGNATURE

Pursuant to therequirementsoftheSecuritiesExchangeAct of1934,theregistrant hasduly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

	HELIUS MEDICAL TECHNOLOGIES, INC.
Dated:  June 13, 2019	By:	/s/ Joyce LaViscount
		Joyce LaViscount, Chief Financial Officer